Management of NSTEMI in Patients with a History of Subdural Hemorrhage

Initial Management

The American Heart Association recommends administering aspirin 162-325 mg (non-enteric formulation, orally or chewed) as soon as possible after hospital presentation, as this remains the cornerstone of NSTEMI therapy even in patients with bleeding risk 1, 2
The American College of Cardiology suggests admitting patients to a monitored unit with continuous rhythm monitoring for at least 24 hours (or until PCI, whichever comes first) 3
Supplemental oxygen should be administered if arterial oxygen saturation is <90% 4
Nitroglycerin should be considered for ongoing ischemic symptoms unless contraindicated (systolic BP <90 mmHg, severe bradycardia, tachycardia without heart failure, right ventricular infarction, or recent use of phosphodiesterase inhibitors) 4
Beta-blockers should be initiated to reduce myocardial oxygen demand by decreasing heart rate, blood pressure, and myocardial contractility 4

High-sensitivity cardiac troponin (hs-cTn) measurement should be performed serially for both diagnosis and prognostic assessment 3
Echocardiography should be conducted to evaluate regional and global left ventricular function 3
Hemodynamic stability, presence of ongoing ischemia, and risk factors for adverse outcomes should be assessed to determine management approach 4

Aspirin monotherapy (75-162 mg daily) is recommended as the safest initial approach for patients with a history of subdural hemorrhage 1, 5
P2Y12 inhibitor therapy (clopidogrel, ticagrelor, prasugrel) should be delayed until after coronary angiography to assess coronary anatomy and bleeding risk 1, 6
Prasugrel is contraindicated in patients with prior history of stroke or TIA 5
Unfractionated heparin (UFH) is the preferred anticoagulant due to its short half-life and reversibility 1, 6

A conservative strategy may be preferred for lower-risk patients without ongoing ischemia to minimize bleeding risk 1, 6
For patients managed conservatively, aspirin should be continued indefinitely, and P2Y12 inhibitor therapy (if used) should be considered for a shorter duration 5, 6
For patients with ongoing ischemia refractory to medical therapy or hemodynamic instability, an early invasive strategy with cardiac catheterization is recommended despite bleeding risk 4

Aspirin should be continued indefinitely 6, 3
The duration of P2Y12 inhibitor therapy should be individualized based on the assessment of bleeding versus thrombotic risk 5
Beta-blockers should be initiated for all patients unless contraindicated 3
ACE inhibitors should be considered for patients with heart failure, LV dysfunction (LVEF <0.40), hypertension, or diabetes 3
ARBs should be considered for ACE inhibitor-intolerant patients 3

NSAIDs (except for aspirin) should be avoided during hospitalization due to increased risks of mortality, reinfarction, hypertension, heart failure, and myocardial rupture 7
Immediate-release dihydropyridine calcium channel blockers should not be administered without adequate beta-blockade 7
Intravenous ACE inhibitors should be avoided within the first 24 hours due to increased risk of hypotension 7
Patients who have received nitrates must not take PDE5 inhibitors (sildenafil within 24 hours, tadalafil within 48 hours) due to potentially dangerous hypotensive effects 4